These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27617040)

  • 1. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.
    Gu X; Chen N; Wei C; Liu S; Papadimitrakopoulou VA; Herbst RS; Lee JJ
    Stat Biosci; 2016 Jun; 8(1):99-128. PubMed ID: 27617040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents.
    Guo B; Yuan Y
    J Am Stat Assoc; 2017; 112(518):508-520. PubMed ID: 32863478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
    Liu Y; Kairalla JA; Renfro LA
    Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial design with Bayesian adaptive randomization and predictive probability.
    Yin G; Chen N; Lee JJ
    J R Stat Soc Ser C Appl Stat; 2012 Mar; 61(2):219-35. PubMed ID: 24259753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling.
    Zang Y; Guo B; Han Y; Cao S; Zhang C
    Stat Med; 2019 Jul; 38(15):2883-2896. PubMed ID: 30968435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Signature Enrichment Design with Bayesian Adaptive Randomization.
    Xia F; George SL; Ning J; Li L; Huang X
    J Appl Stat; 2021; 48(6):1091-1110. PubMed ID: 34024982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Enrichment Designs in Clinical Trials.
    Thall PF
    Annu Rev Stat Appl; 2021 Mar; 8(1):393-411. PubMed ID: 36212769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian adaptive design with biomarkers for targeted therapies.
    Eickhoff JC; Kim K; Beach J; Kolesar JM; Gee JR
    Clin Trials; 2010 Oct; 7(5):546-56. PubMed ID: 20571131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the design and conduct of the BATTLE trials.
    Liu S; Lee JJ
    Chin Clin Oncol; 2015 Sep; 4(3):33. PubMed ID: 26408300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
    Antoniou M; Kolamunnage-Dona R; Jorgensen AL
    J Pers Med; 2017 Jan; 7(1):. PubMed ID: 28125057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.